Ocular Therapeutix Announces Upcoming Presentation of Interim OTX-TKI Phase 1 Clinical Trial Data at Angiogenesis, Exudation, and Degeneration 2022 Meeting and OTX-TIC Phase 1 Clinical Trial at Glaucoma 360

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced its intention to present data at two medical meetings. Data from the Phase 1 Australian-based clinical trial of OTX-TKI, an axitinib intravitreal implant for the treatment of patients with wet age-related macular degeneration (wet AMD) and other retinal diseases, will be presented at the Angiogenesis, Exudation, and Degeneration 2022 Meeting being held on February 11-12th. The Company will also present data from the Phase 1 US-based clinical trial of OTX-TIC, an intracameral implant of travoprost for the treatment of glaucoma and ocular hypertension at the Glaucoma 360 Meeting on February 11th.

Details of Ocular’s Presentation at Angiogenesis, Exudation, and Degeneration 2022 Meeting are as follows:

TITLE: Update on OTX-TKI Clinical Trials for Macular Disease
PRESENTER: Andrew A. Moshfeghi, MD, MBA, Associate Professor of Clinical Ophthalmology; Medical Director of the USC Roski Eye Institute; Director of Clinical Trials; Director of the Vitreoretinal Surgery Fellowship Program; and Director of the Medical Retina Fellowship Program
PRESENTATION DATE AND TIME: Saturday, February 12, 2022, 8:40 a.m. ET

Details of Ocular’s Presentation at Glaucoma360 are as follows:

TITLE: OTX-TIC, An Intracameral Hydrogel-based Travoprost Implant to Treat Patients with Glaucoma and Ocular Hypertension
PRESENTER: Dr. Michael Goldstein, MD, MBA, President, Ophthalmology and Chief Medical Officer, Ocular Therapeutix
PRESENTATION DATE AND TIME: Saturday, February 11, 2022, 11:39 a.m. ET start of session

“We are pleased to be presenting updated data on both OTX-TKI and on OTX-TIC at these medical meetings,” said Michael Goldstein, MD, MBA, President, Ophthalmology and Chief Medical Officer of Ocular Therapeutix. “OTX-TKI is an intravitreal implant of axitinib delivered via injection, leveraging a new administration and novel mechanism of action for the treatment of patients with wet AMD and other retinal diseases. This latest analysis of interim data from our ongoing Phase 1 trial in Australia in subjects with subretinal and/or intraretinal fluid due to wet AMD continues to support the product’s safety profile and preliminary biological activity signaling a clinically-meaningful decrease in intraretinal and/or subretinal fluid. We are seeing extended duration of activity with over 60% of subjects across all cohorts with a duration of activity of six months or more that could represent a compelling drug product profile.”